KPO: Dialysate Concentrate For Hemodialysis (Liquid Or Powder)
What it covers
A hemodialysis system and accessories is a device that is used as an artificial kidney system for the treatment of patients with renal failure or toxemic conditions and that consists of an extracorporeal blood system, a conventional dialyzer, a dialysate delivery system, and accessories. Blood from a patient flows through the tubing of the extracorporeal blood system and accessories to the blood compartment of the dialyzer, then returns through further tubing of the extracorporeal blood system to the patient. The dialyzer has two compartments that are separated by a semipermeable membrane. While the blood is in the blood compartment, undesirable substances in the blood pass through the semipermeable membrane into the dialysate in the dialysate compartment. The dialysate delivery system controls and monitors the dialysate circulating through the dialysate compartment of the dialyzer.
(1) The extracorporeal blood system and accessories consists of tubing, pumps, pressure monitors, air foam or bubble detectors, and alarms to keep blood moving safely from the blood access device and accessories for hemodialysis (§ 876.5540) to the blood compartment of the dialyzer and back to the patient.
(2) The conventional dialyzer allows a transfer of water and solutes between the blood and the dialysate through the semipermeable membrane. The semipermeable membrane of the conventional dialyzer has a sufficiently low permeability to water that an ultrafiltration controller is not required to prevent excessive loss of water from the patient's blood. This conventional dialyzer does not include hemodialyzers with the disposable inserts (Kiil type) (§ 876.5830) or dialyzers of high permeability (§ 876.5860).
(3) The dialysate delivery system consists of mechanisms that monitor and control the temperature, conductivity, flow rate, and pressure of the dialysate and circulates dialysate through the dialysate compartment of the dialyzer. The dialysate delivery system includes the dialysate concentrate for hemodialysis (liquid or powder) and alarms to indicate abnormal dialysate conditions. This dialysate delivery system does not include the sorbent regenerated dialysate delivery system for hemodialysis (§ 876.5600), the dialysate delivery system of the peritoneal dialysis system and accessories (§ 876.5630), or the controlled dialysate delivery system of the high permeability hemodialysis system § 876.5860).
(4) Remote accessories to the hemodialysis system include the unpowered dialysis chair without a scale, the powered dialysis chair without a scale, the dialyzer holder set, dialysis tie gun and ties, and hemodialysis start/stop tray.
The identification in 21 CFR 876.5820, hemodialysis system and accessories. FDA gives KPO no definition of its own, so the regulation’s describes it.
FDA flags KPO devices as life-sustaining or life-supporting.
Recent clearances
| 510(k) | Device | Applicant | Decision | Type |
|---|---|---|---|---|
| K260799 | Nipro Dry Acid Concentrate Mixer | Nipro Technical Solutions, Incoporated | Aug 19, 2026 | Traditional |
| K253462 | NaturaLyte® Dry Bicarbonate Concentrate (08-4112-2) | Fresenius Medical Care Renal Therapies Group, LLC | Jan 29, 2026 | Traditional |
| K252180 | Bicarby Dialysate RFP-404 (RFP-404-W); Bicarby Dialysate RFP-403 (RFP-403-W); Bicarby Dialysate RFP-403 (RFP-403-G); Bicarby Dialysate RFP-453 (RFP-453-W); Bicarby Dialysate RFP-453 (RFP-453-G); Bicarby Dialysate RFP-454 (RFP-454-W); Bicarby Dialysate RFP-454 (RFP-454-G); Bicarby Dialysate RFP-456 (RFP-456-W) | Fresenius Medical Care Renal Therapies Group, LLC | Sep 9, 2025 | Traditional |
| K243786 | Bicarby Dialysate RFP-402 (RFP-402-G); Bicarby Dialysate RFP-400 (RFP-400-G); Bicarby Dialysate RFP-407 (RFP-407-G); Bicarby Dialysate RFP-401 (RFP-401-G); Bicarby Dialysate RFP-404 (RFP-404-G); Bicarby Dialysate RFP-456 (RFP-456-G); Ci-Ca Dialysate 2K (RFP-457-G); Ci-Ca Dialysate 4K (RFP-458-G) | Fresenius Medical Care Renal Therapies Group, LLC | Apr 4, 2025 | Traditional |
| K240920 | HemoCare Bicarbonate Concentrate Set (BCS) | Deka Research and Development | Jul 12, 2024 | Traditional |
| K233950 | pureFLOW 402 (F00012067); pureFLOW 406 (F00012068); pureFLOW 401 (F00012069); pureFLOW 400 (F00012070) | Fresenius Medical Care Renal Therapies Group, LLC | May 10, 2024 | Traditional |
| K233213 | NxStage PureFlow Solution | Nxstage Medical, Inc. | Jan 18, 2024 | Traditional |
| K233159 | pureFLOW 402, pureFLOW 400, pureFLOW 406, pureFLOW 401, pureFLOW 502, pureFLOW 504 | Fresenius Medical Care Renal Therapies Group, LLC | Dec 1, 2023 | Traditional |
| K223431 | Citric Complete Liquid Citric Acid Concentrate | Nipro Renal Solutions USA, Corp. | Aug 4, 2023 | Traditional |
| K221652 | NIKKICART | Renal Care Dialysis Solutions, S.A. DE C.V. | Mar 3, 2023 | Traditional |
Clearances by year
31 KPO 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.
| Year | Clearances | Median days to decision |
|---|---|---|
| 2026 (so far) | 2 | 138 |
| 2025 | 2 | 88 |
| 2024 | 3 | 112 |
| 2023 | 3 | 263 |
| 2022 | 2 | 489 |
| 2021 | 1 | 23 |
| 2020 | 5 | 270 |
| 2018 | 2 | 267 |
| 2017 | 3 | 192 |
| 2016 | 1 | 206 |
| 2015 | 1 | 235 |
| 2014 | 2 | 344 |
| 2013 | 1 | 87 |
| 2012 | 2 | 99 |
| 2011 | 1 | 264 |
Who submits
18 applicants cleared a KPO device since 2011. 90% of the clearances went to applicants in United States, then Italy (6%) and Mexico (3%). By type: Traditional 90% and Special 10%.
| Applicant | Clearances since 2011 |
|---|---|
| Fresenius Medical Care Renal Therapies Group, LLC | 10 |
| Di-Chem, Inc. | 2 |
| Haemopharm Biofluids S.R.L. | 2 |
| Isopure, Corp. | 2 |
| Nipro Renal Solutions USA, Corp. | 2 |
| B. Braun Avitum AG | 1 |
| Baxter Healthcare Corporation | 1 |
| Deka Research and Development | 1 |
How FDA classifies it
(1) Class II (performance standards) for hemodialysis systems and all accessories directly associated with the extracorporeal blood system and the dialysate delivery system.
(2) Class I for other accessories of the hemodialysis system remote from the extracorporeal blood system and the dialysate delivery system, such as the unpowered dialysis chair, hemodialysis start/stop tray, dialyzer holder set, and dialysis tie gun and ties. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
From 21 CFR 876.5820. Special controls are the requirements a 510(k) must show it meets.
Standards
21 CFR 876.5820 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent KPO clearances declared.
Ask about KPO
Questions about KPO
What is FDA product code KPO?
Product code KPO, “Dialysate Concentrate For Hemodialysis (Liquid Or Powder)” in FDA's classification database, is a Class II device type under 21 CFR 876.5820 (hemodialysis system and accessories), reviewed by FDA's Gastroenterology, Urology panel. FDA's 510(k) database lists 124 clearances under KPO, 31 of them since 2011.
How many 510(k) clearances are there under KPO?
FDA’s 510(k) database listed 124 clearances under KPO as of Oct 29, 2026, 31 of them decided since 2011; the most recent decision was Aug 19, 2026. The Predicate Finder searches the live database.
How long does FDA take to clear a KPO 510(k)?
For the 4 KPO clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 115 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.
Which companies have the most KPO clearances?
Since 2011: Fresenius Medical Care Renal Therapies Group, LLC (10), Di-Chem, Inc. (2), Haemopharm Biofluids S.R.L. (2), Isopure, Corp. (2) and Nipro Renal Solutions USA, Corp. (2). 18 applicants have cleared a KPO device in that time.